lu codes
Source: ODB Formulary/CDI, edition 43 (effective 2026-04-28). Checked weekly for updates. Unofficial search tool.
/
showing 10 of 39 drugs (120 codes)
BOTULINUM TOXIN TYPE A Botox
For the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older.
1 year
For adult patients with urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury who fail to respond to behavioural medication and anticholinergics and/or are intolerant to anticholinergics.
1 year
The recommended dose is 200U injected into the detrusor muscle.
Subsequent injections should be provided at intervals of no less than every 36 weeks and patients who fail to respond to initial treatment with Botulinum Toxin Type A should not be retreated.
For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have:
1 year
Failed to respond to behavioral techniques AND had an inadequate response or intolerance to adequate trials (i.e., at least 2 weeks at the maximum tolerated dose) of at least two medications for overactive bladder (e.g. anticholinergics, mirabegron).
The recommended dose is 100U injected into the detrusor muscle.
NOTES:
-Patients who fail to achieve a reduction of greater than 50 percent in the frequency of urinary incontinence episodes with 1 dose should not be retreated.
-Maximum 3 doses per year in responders, at a frequency of no more than once every 12 weeks.
-Patients must have a post-void residual (PVR) urine volume of less than 150mL.
Note: Botox should be administered personally by a urologist, pediatrician, neurologist, physical medicine specialist or a physician with equivalent post-graduate training and experience with neuromuscular or urological disorders as appropriate.
FLUNARIZINE HCL Sibelium, Flunarizine
For patients with migraine headaches who have not responded to propranolol.
1 year
For patients who have tried propranolol and experienced significant adverse effects.
1 year
For patients in whom propranolol is contraindicated.
1 year
Contraindicated in patients with clinical depression and in patients with extrapyramidal disorders.
LEVODOPA & CARBIDOPA Sinemet CR, AA-Levocarb CR
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Indefinite
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Indefinite
BOTULINUM TOXIN TYPE A, INCOBOTULINUMTOXINA, ABOBOTULINUM TOXIN A Botox, Xeomin, Dysport Therapeutic
To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.
1 year
For the management of focal spasticity, due to stroke or spinal cord injury in adults.
1 year
TACROLIMUS Prograf, Sandoz Tacrolimus, Ach-Tacrolimus, Advagraf, Sandoz Tacrolimus XR, Envarsus PA
For solid organ transplant and bone marrow transplant.
Indefinite
For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants
Indefinite
For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants.
Indefinite
TICLOPIDINE HCL Ticlid, Ticlopidine
Who are known to be, or become, intolerant of ASA;
Indefinite
Where ASA is contraindicated;
Indefinite
Who continue to have TIA or stroke symptoms while being treated with ASA.
Indefinite
ETIDRONATE DISODIUM Didronel, Co Etidronate
For the treatment of Paget's disease;
Indefinite
For the management of hypercalcemia of malignancy.
Indefinite
URSODIOL Urso, PMS-Ursodiol C, GLN-Ursodiol, Jamp-Ursodiol, AG-Ursodiol, Ursodiol C +2 more
For the treatment of primary biliary cirrhosis.
Indefinite
For the treatment of primary sclerosing cholangitis.
Indefinite
For the treatment of primary sclerosing cholangitis.
Indefinite
CLODRONATE DISODIUM Ostac, Clasteon
For the control and prophylaxis of hypercalcemia of malignancy.
Indefinite
For the treatment of bony metastases in patients with breast cancer.
Indefinite
For the prevention and treatment of osteolytic lesions in patients with multiple myeloma.
Indefinite
ZOLEDRONIC ACID Aclasta, Zoledronic Acid Injection
For the treatment of Paget's disease.
Indefinite
For the treatment of osteoporosis in postmenopausal females who meet the following criteria:
Indefinite
- High risk* for fracture; and
- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.
*High fracture risk is defined as either:
- a prior fragility fracture AND a moderate 10-year fracture risk (10% to 20%) based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR
- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR
- where a patient's 10-year fracture risk based on the CAROC or FRAX tool, is less than the thresholds defined above, a high fracture risk based on evaluation of clinical risk factors for fracture
Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors.
For the treatment of osteoporosis in males who meet the following criteria:
Indefinite
- High risk* for fracture; and
- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.
*High fracture risk is defined as either:
- a moderate 10-year fracture risk (10% to 20%) with a prior fragility fracture based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR
- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR
- where the patient's 10-year fracture risk is below 10% based on the CAROC or FRAX tool, a high fracture risk based on evaluation of clinical risk factors for fracture
Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors.
In all cases, patients receiving Aclasta should not be receiving concomitant bisphosphonate therapy. The recommended dose of Aclasta (zoledronic acid) is a single IV injection of 5mg, once yearly.
No matching LU codes found.